Macrolides for the treatment of COVID-19: a living, systematic review

Randomized trials evaluating macrolide use in the treatment of coronaviruses showed no beneficial effects compared to standard of care. The evidence for all outcomes is inconclusive. Larger trials are needed to determine the effects of Macrolides on pulmonary and other outcomes.

Estimation of the basic reproduction number, average incubation time, asymptomatic infection rate, and case fatality rate for COVID-19: Meta-analysis and sensitivity analysis

SARS-CoV-2 causes severe acute respiratory syndrome coronavirus 2. The average incubation time is 5.08 days.

Rehabilitation setting during and after Covid-19: An overview on recommendations

Review of studies on the effect of coronavirus 2019 on rehabilitation services. For patients, an integrated rehabilitative process is recommended.

Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A Systematic Review

African American/Black and Hispanic populations experience disproportionately higher rates of SARS-CoV-2 infection, hospitalization, and COVID-19-related mortality

A systematic review and meta-analysis of published research data on COVID-19 infection fatality rates

An important unknown during the coronavirus disease- 2019 (COVID-19) pandemic has been the infection fatality rate (IFR) IFR is increasingly being called for as an estimate of overall mortality.

Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial

We aimed to compare the efficacy and safety of nab-paclitaxel plus gemcitabine with nab-Paclitaxel plus gemcitabine. Adults (aged 18–75 years) with an Eastern Cooperative Oncology Group were randomly assigned. Median overall survival was 18.5 months (95% CI 14.4–21.5) in the nab.-paclitaxel group and 20.7 months in the fOLFIRinoX group.

Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study

Radical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. Serious adverse events associated with organ preservation were most commonly due to rectal bleeding or pain. Short-course radiotherapy followed by transanal endoscopic microsurgery achieves high levels of organ preservation.

Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study

The study aims to investigate the impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England. By October 2020, the monthly rate had returned to 2019 levels but did not exceed it. Over 3500 fewer people had been diagnosed and treated for colorectal cancer in England than would have been expected.

Departments

Recent Posts